Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT IN NOVEMBER OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 17,871 SHARES OF EVOLUS AND AN AGGREGATE OF 45,063 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 13 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPAN.

EVOLUS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. OUR THIRD QUARTER RESULTS REFLECT DOUBLE-DIGIT GROWTH DESPITE THE CURRENT MARKET ENVIRONMENT. OUR CONTINUED ABOVE MARKET PERFORMANCE AND DISCIPLINED EXPENSE MANAGEMENT, CREATE AN IMPORTANT TRANSITION POINT FOR THE COMPANY, AS WE CONTINUE TO EXPEC.

EVOLUS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AND INVESTOR MEETINGS AT THE UPCOMING STIFEL HEALTHCARE CONFERENCE. THE FIRESIDE CHAT WILL TAKE PLACE ON TUESDAY, NOVEMBER 11, 2025, AT 11:20 AM ET. THE FIRESIDE CHAT CAN BE ACCESSED ON THE INVESTOR RELATIONS PAGE OF THE EVOLUS WEBSITE HERE. A REPLAY.

EVOLUS TO PARTICIPATE IN 2025 STIFEL HEALTHCARE CONFERENCE

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT IT WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, NOVEMBER 5, 2025, AFTER THE U.S. FINANCIAL MARKETS CLOSE. EVOLUS MANAGEMENT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS THESE RESULTS AT 4:30 P.M. ET THAT SAME DAY. A QUESTION-AND-ANSWER SESSION WILL FOLLOW MANAGEMENT'S REMARKS. T.

EVOLUS TO REPORT THIRD QUARTER FINANCIAL RESULTS ON NOVEMBER 5, 2025

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT IN OCTOBER OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 24,931 SHARES OF EVOLUS AND AN AGGREGATE OF 31,116 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 9 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'.

HEADLINE SUMMARY: BOARD-CERTIFIED PLASTIC SURGEON BRINGS EXTENSIVE EXPERTISE IN FACIAL ANATOMY AND INJECTABLE TREATMENTS TO SUPPORT NATIONWIDE ROLLOUT OF BREAKTHROUGH HYALURONIC ACID TECHNOLOGY. PARTNERSHIP UNDERSCORES EVOLUS' COMMITMENT TO PATIENT SAFETY AND PROVIDER EDUCATION FOR THEIR NEW FDA-APPROVED FILLER LINE.

TOP MIAMI PLASTIC SURGEON DR. BENJAMIN ESKENAZI NAMED LEAD CONSULTANT FOR EVOLUS' EVOLYSSE FILLER LAUNCH

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 8,744 SHARES OF EVOLUS COMMON STOCK AND AN AGGREGATE OF 15,000 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 6 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY, AND 143,403 SHARES OF EVOLUS COMMON STOCK AND 104,603 RSUS OF THE COM.

EVOLUS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THE APPOINTMENT OF TATJANA MITCHELL AS ITS CHIEF FINANCIAL OFFICER, EFFECTIVE SEPTEMBER 8, 2025. MS. MITCHELL HAS OVER 20 YEARS OF STRATEGIC AND OPERATIONAL FINANCE LEADERSHIP ACROSS BOTH PUBLIC AND PRIVATE COMPANIES IN RETAIL, CONSUMER, DATA, AND TECHNOLOGY-DRIVEN BUSINESSES. SHE BRINGS A PROVEN TRACK RECORD OF DRI.

EVOLUS ANNOUNCES THE APPOINTMENT OF TATJANA MITCHELL AS CHIEF FINANCIAL OFFICER

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM A U.S. PIVOTAL STUDY OF EVOLYSSE SCULPT, AN INJECTABLE HYALURONIC ACID (HA) GEL PRODUCT DESIGNED TO RESTORE MID-FACE VOLUME. ACHIEVING POSITIVE TOPLINE RESULTS IN OUR MID-FACE STUDY IS AN IMPORTANT MILESTONE FOR EVOLUS AS WE EXPAND BEYOND JEUVEAU WITH THE EVOLYSSE LINE, SAID DAVID.

EVOLUS ANNOUNCES POSITIVE DATA FROM PIVOTAL TRIAL FOR EVOLYSSE SCULPT INJECTABLE HYALURONIC ACID GEL PRODUCT AT 2025 COSMETIC BOOTCAMP

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT IT HAS SUBMITTED THE FINAL MODULE OF ITS PREMARKET APPROVAL (PMA) APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR EVOLYSSE SCULPT, AN INJECTABLE HYALURONIC ACID (HA) GEL PRODUCT DESIGNED TO RESTORE MID-FACE VOLUME. THIS SUBMISSION REPRESENTS AN IMPORTANT MILESTONE IN EXPANDING OUR EVOLYSSE COL.

EVOLUS ANNOUNCES SUBMISSION OF PREMARKET APPROVAL APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR EVOLYSSE SCULPT INJECTABLE HYALURONIC ACID GEL PRODUCT

Evolus, Inc.

EOLS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Evolus, Inc.

EOLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EOLS